Osmosis Investment Management UK Ltd Acquires Shares of 3,240 Danaher Corporation $DHR

Osmosis Investment Management UK Ltd bought a new position in shares of Danaher Corporation (NYSE:DHRFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 3,240 shares of the conglomerate’s stock, valued at approximately $617,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Danaher during the 2nd quarter worth approximately $10,492,520,000. Norges Bank purchased a new stake in Danaher in the 4th quarter worth $2,177,106,000. Generation Investment Management LLP acquired a new position in Danaher during the second quarter worth $1,287,949,000. Flossbach Von Storch SE purchased a new position in Danaher during the second quarter valued at $747,260,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Danaher in the second quarter valued at about $712,875,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR opened at $215.78 on Wednesday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The firm has a market capitalization of $151.69 billion, a PE ratio of 38.33, a PEG ratio of 2.68 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average price is $197.17 and its 200 day moving average price is $192.36.

Danaher (NYSE:DHRGet Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on DHR shares. TD Cowen reduced their price target on shares of Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. DZ Bank began coverage on Danaher in a research note on Wednesday, June 3rd. They set a “buy” rating and a $210.00 price objective for the company. Wells Fargo & Company reduced their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Piper Sandler assumed coverage on Danaher in a research report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price on the stock. Finally, Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Check Out Our Latest Report on Danaher

Danaher Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Further Reading

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.